Research object：Planned to receive pyrrolidine for HER2 positive first-line breast cancer patients
Research purpose:
Main research objectives:
To observe the efficacy and safety of pyrrolidine in the treatment of HER2 positive advanced first-line breast cancer.
Secondary research objectives:
1. Evaluate the correlation between patient characteristics in the late stage of treatment and specific treatment plans and clinical outcomes Sex (including safety outcomes)
2. Evaluate whether and how previous anti HER2 therapy affects the efficacy of subsequent pyrrolitinib treatment
3. To observe the efficacy of pyrrolitinib in patients with brain metastasis of HER2 positive breast cancer
Research endpoint:
Main research endpoint:
Progression free survival (rwPFS)
Secondary study endpoint:
Efficacy endpoints: objective response rate (rwORR), disease control rate (rwDCR), until treatment failure Time to Flight (TTF), Total Survival (OS), Security

开始日期2026-04-01

申办/合作机构

天津市肿瘤医院（天津医科大学肿瘤医院）

NCT07417241

/ Not yet recruiting临床2期IIT

Efficacy and Safety of SHR-A1811 Versus Pyrotinib Plus Capecitabine in Patients With Trastuzumab Primary-Resistant HER2-Positive Advanced Breast Cancer：A Prospective, Multicenter, Open-Label, Randomized, Controlled Study

This is a prospective, multicenter, open-label, randomized, controlled Study. The purpose of this study is to evaluate the efficacy and safety of SHR-A1811 versus pyrotinib plus capecitabine in the treatment of trastuzumab primary-resistant HER2-positive advanced breast cancer.

开始日期2026-03-31

申办/合作机构

北京肿瘤医院（北京大学肿瘤医院）

NCT07470203

/ Not yet recruitingN/AIIT

Efficacy and Safety of Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer：A Prospective, Single-Arm, Observational, Real-World Study

This is a Prospective, Single-Arm, Observational, Real-World Study. The purpose of this study is to evaluate the safety and efficacy of pyrotinib combined with trastuzumab and pertuzumab for maintenance therapy in HER2-positive advanced breast cancer in the real-world setting.

开始日期2026-03-31

申办/合作机构-

100 项与马来酸吡咯替尼相关的临床结果

登录后查看更多信息

100 项与马来酸吡咯替尼相关的转化医学

登录后查看更多信息

100 项与马来酸吡咯替尼相关的专利（医药）

登录后查看更多信息

373

项与马来酸吡咯替尼相关的文献（医药）

2026-03-01·JOURNAL OF ETHNOPHARMACOLOGY

Shenling Baizhu powder alleviates pyrotinib-induced diarrhea via CFTR-activated chloride secretion

Article

作者: Wang, Jingliang ; Jiang, Fengxian ; Liu, Lei ; Zhao, Jing ; Shu, Yang ; Qi, Fanghua ; Pan, Liying ; Fu, Guobin ; Lai, Jingjiang ; Ran, Pancen ; Xu, Wei ; Yuan, Xiaotian

ETHNOPHARMACOLOGICAL RELEVANCE:

Shenling Baizhu Powder (SBP), a classic traditional Chinese medicine formula documented in Taiping Huimin Heji Jufang, has been widely used in the management of gastrointestinal disorders. Pyrotinib, a tyrosine kinase inhibitor employed in cancer treatment, is frequently associated with chemotherapy-induced diarrhea.

PURPOSE:

This study aimed to investigate the effect of pyrotinib on intestinal chloride secretion and to evaluate the therapeutic potential and underlying mechanism of SBP against pyrotinib-induced diarrhea.

METHODS:

Twenty-four rats were randomly divided into four groups: control, SBP, pyrotinib, and pyrotinib + SBP. Intestinal chloride secretion and channel activity were assessed using the Ussing chamber system. Network pharmacology analysis was performed to predict the signaling pathways involved in SBP-mediated cystic fibrosis transmembrane conductance regulator (CFTR) regulation. A two-sample Mendelian randomization (MR) analysis was further conducted to examine causal relationships between key targets identified through network pharmacology and CFTR, using summary-level genetic data. Western blot analysis was used to validate the predicted signaling pathway.

RESULTS:

SBP administration significantly alleviated diarrhea symptoms and restored electrolyte homeostasis in pyrotinib-treated rats. Ussing chamber experiments using rat ileal tissues and T84 cell models demonstrated that SBP effectively inhibited chloride ion secretion through suppression of the CFTR channel. Analysis based on network pharmacology revealed SBP as a potential regulator of CFTR, acting through Epidermal Growth Factor (EGF)-mediated cyclic adenosine monophosphate (cAMP) signaling. MR analysis provided supporting evidence for a causal effect of EGF on CFTR (p = 0.039). Experimental validation confirmed that SBP downregulated EGF and cAMP expression, consequently attenuating CFTR-mediated chloride secretion.

CONCLUSION:

SBP ameliorates pyrotinib-induced diarrhea by modulating the EGF-cAMP-CFTR signaling axis, thereby inhibiting intestinal chloride secretion and restoring electrolyte balance. In addition to confirming its therapeutic effect, this study reveals a previously unrecognized mechanism whereby SBP downregulates EGFR-dependent CFTR activation, offering a mechanistic explanation for its antidiarrheal properties. These findings not only highlight the mechanistic novelty of SBP in the context of targeted-therapy-associated diarrhea but also provide a scientific foundation supporting its clinical application and future translational development.

2026-03-01·DRUG METABOLISM AND DISPOSITION

In vitro metabolism studies of 5 acrylamide covalent drugs: Comparison with metabolism and disposition in human

Article

作者: Li, Ruixing ; Shen, Liang ; Tao, Yi ; Cao, Weiqun ; Shi, Qingfeng ; Zhu, Mingshe

Targeted covalent inhibitors, such as acrylamide covalent drugs (ACDs), offer advantages in potency, selectivity, and duration of effect compared with traditional small-molecule inhibitors. However, ACDs undergo unique biotransformation pathways in humans, including CYP-mediated metabolism, protein covalent binding, and nonenzymatic glutathione (GSH) adduction, which make standard in vitro metabolism assays for small molecules unsuitable for characterizing ACDs. This study aimed to develop a specialized panel of in vitro metabolism experiments for characterizing ACDs. The approach included metabolism stability assays in human liver microsomes with or without NADPH, covalent binding to human serum albumin with or without GSH, and metabolite profiling in human liver microsomes with or without GSH. In vitro metabolic data were generated for 5 ACDs, abivertinib, afatinib, osimertinib, ibrutinib, and pyrotinib, and compared with reported human metabolism and disposition data. In general, in vitro biotransformation pathways determined in this study are consistent with major metabolic clearance pathways observed in humans. For example, osimertinib showed the highest nonspecific protein covalent binding, a high oxidation-to-GSH adduct ratio, and moderate NADPH-dependent metabolic rates, supporting protein covalent binding as the major metabolic pathway in humans. In contrast, afatinib exhibited minimal CYP-mediated metabolism after accounting for covalent binding to microsomal proteins, low serum protein binding, and a very low oxidation-to-GSH adduct ratio, consistent with GSH adduction being the predominant biotransformation pathway in humans. The results demonstrate that the newly developed in vitro metabolism workflow enables more accurate predictions of CYP-mediated clearance rates and clarifies the relative contributions of CYP metabolism, nonspecific protein covalent binding, and GSH adduction to overall metabolic clearance in humans. SIGNIFICANT STATEMENT: This study established a novel in vitro metabolism approach for characterizing acrylamide covalent drugs. By comparing in vitro metabolic data for abivertinib, afatinib, osimertinib, ibrutinib, and pyrotinib with reported human metabolism and disposition data, we demonstrated that this method improves the accuracy of predicting CYP-mediated metabolic rates. Furthermore, it provides clearer insights into the relative contributions of CYP metabolism, nonspecific protein covalent binding, and glutathione adduction to the overall metabolic clearance of acrylamide covalent drugs in humans.

2026-02-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

CD24 overexpression confers resistance to Pyrotinib through inhibiting autophagy in patients with HER2-positive breast cancer

Article

作者: Li, Xichuan ; Gao, Yue ; Yang, Jiming ; Zhou, Xinglu ; Yan, Zhangdi ; Lu, Yi ; Fu, Zhenkun ; Deng, Bao ; Zhong, Lei

Human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) constitutes the most challenging subtype of BC, characterized by aggressive tumor proliferation, rapid metastatic potential, and a high propensity for developing resistance, which collectively contribute to a poor clinical prognosis. While the introduction of the novel HER2 inhibitor Pyrotinib has significantly improved therapeutic outcomes, its effectiveness as a monotherapy was substantially constrained by the emergence of acquired resistance. Consequently, discovering novel targeted agents to enhance Pyrotinib's therapeutic effectiveness through combination therapy was urgently required. Cluster of differentiation 24 (CD24) has been identified as a novel immune checkpoint that contributes to tumor-associated immune suppression, however, its involvement in resistance to Pyrotinib remains inadequately understood. In this study, we elucidated the role of CD24 in Pyrotinib-resistant HER2+ BC. Our results demonstrated that CD24 expression was elevated in Pyrotinib-resistant HER2+ BC cells. In vitro experiments revealed that silencing CD24 inhibited proliferation, migration, and invasion of HER2+ BC cells while promoting autophagy, whereas overexpression of CD24 produced opposite effects. Furthermore, CD24 knockdown reduced its expression level by promoting the ubiquitination modification of epidermal growth factor receptor (EGFR), and significantly inhibited its downstream AKT/mTOR signaling pathway. By interacting with EGFR and modulating the mTOR pathway, CD24 acted as a critical regulator of autophagic cell death, thereby enhancing the sensitivity of HER2+ BC cells and reversing Pyrotinib resistance.

863

项与马来酸吡咯替尼相关的新闻（医药）

2026-04-02

·协和医智库

科研新知 | 徐兵河院士团队：PHILA研究再度登顶BMJ，PyroHT方案夯实HER2阳性晚期乳腺癌一线治疗地位

2026年3月16日，中国医学科学院肿瘤医院徐兵河院士团队在《英国医学杂志》（BMJ）在线发表了题为“Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial”的研究成果。乳腺癌是全球高发的恶性肿瘤，发病率居女性恶性肿瘤首位，素有“红颜杀手”之称。近年来，我国在乳腺癌创新靶向药物研发与临床治疗方案上持续突破，整体诊疗水平稳步提升，已接轨国际水平。尽管乳腺癌诊疗取得显著进展，但部分患者仍面临长期复发和死亡风险。以HER2阳性乳腺癌为例，曲妥珠单抗虽已广泛应用于HER2阳性早期乳腺癌（新）辅助治疗，但在晚期患者的治疗中，如何应对曲妥珠单抗经治人群的耐药困境及高发的脑转移，仍是临床实践中面临的两大挑战，直接影响着患者的生存质量与预后。原创靶点研发、精准分型新药、破解耐药机制、规范综合治疗及普及早筛早诊，是抗肿瘤治疗领域的重点发力方向。 2023年PHILA研究首次发表于《英国医学杂志》，由吡咯替尼联合曲妥珠单抗、多西他赛（PyroHT）组成的大小分子联合治疗方案，已确立为HER2阳性晚期乳腺癌的一线治疗新选择，为患者提供了中国原研治疗方案。2026年，PHILA研究的长期随访数据再度发表于《英国医学杂志》，实现了该研究的第二次亮相，这不仅进一步验证了其持久的临床价值与深远的学术影响力，更标志着中国原创临床研究正稳步迈向国际前沿。本次更新数据进一步夯实了PyroHT方案在HER2阳性晚期乳腺癌一线治疗中的核心地位，并为“中国方案”走向全球、惠及更多患者奠定了坚实的循证医学基础。 PHILA研究是一项由中国医学科学院肿瘤医院徐兵河院士牵头，基于中国原研药物开展的一项随机、双盲、多中心、Ⅲ期临床试验。该研究采用不可逆的HER2受体酪氨酸激酶抑制剂（TKI）吡咯替尼，联合曲妥珠单抗，通过大小分子协同机制双重抑制HER2信号通路，旨在比较PyroHT方案与曲妥珠单抗联合多西他赛（HT）方案一线治疗HER2阳性晚期乳腺癌的疗效与安全性。作为首个发表于BMJ的中国乳腺癌药物研究，PHILA研究于2023年首次发表，证实了PyroHT方案在无进展生存期（PFS）的显著获益和良好的耐受性，率先突破了国际学术界对中国乳腺癌原研研究的认知壁垒。本次PHILA研究更新的长期数据（45.5个月的中位随访）进一步证实，PyroHT方案可凭借独特的大小分子协同作用机制，有望破解晚期治疗难题，为临床实践带来突破性解决方案。在（新）辅助曲妥珠单抗经治患者中，PyroHT治疗组的PFS长达62.8个月，较对照组延长4年余（10.4个月），疾病进展或死亡风险降低76%（HR=0.24），获益程度优于未经治人群（HR=0.47）。吡咯替尼联合曲妥珠单抗和多西他赛不仅持续延长无进展生存期，更首次在总生存期上显示出明确获益，死亡风险降低26%，5年生存率高达66%。该生存获益幅度与国际标准帕妥珠单抗方案相当，而吡咯替尼作为口服TKI，兼具颅内抗肿瘤的潜在优势。PyroHT治疗可将首次脑转移的发生时间延缓7.5个月（16.6个月 vs. 9.1个月），有望为HER2阳性乳腺癌患者带来更长的生存期，同时推迟脑转移及其相关治疗（如脑部放疗）可能导致的认知功能损害等不良反应，提高患者的生活质量。 PHILA研究中（新）辅助曲妥珠单抗经治患者的PFS 截至2025年5月30日，PHILA研究总生存率更新数据吡咯替尼联合曲妥珠单抗与多西他赛方案展现出显著的长期生存获益，不仅能为曲妥珠单抗经治人群带来明确的无进展生存期与总生存期提升，还可有效延缓脑转移的发生。此次长期随访数据再度发表于BMJ，既体现了国际学术界对PyroHT方案长期有效性与安全性的进一步认可，也标志着中国乳腺癌原研临床研究从“首次突破”迈向“持续引领”。中国医学科学院肿瘤医院徐兵河为论文通讯作者，马飞、闫敏为论文的共同第一作者。论文链接：https://pmc.ncbi.nlm.nih.gov/articles/PMC12990035/ 本文来源：中国医学科学院新闻中心

2026-04-02

·新浪看点

4月开门红!创新药双重利好掀起涨停潮!∽附核心概念股梳理!

$津药药业(SH600488)$ 4月1日，A股四月开门红，截至收盘，上证指数收涨1.46%报3948.55点，深证成指涨1.7%，创业板指涨1.96%，北证50涨2.39%，科创50涨3.33%。两市全天成交额20251亿元。两市个股涨多跌少，合计4492只个股上涨，881只个股下跌。创新药迎基本面+政策双重利好，掀起涨停潮！创新药成为今日盘面绝对主线，多股20CM涨停，传统医药股同步走强。一方面，医药流通行业数字化、AI赋能加速，头部集中度持续提升；另一方面，国产创新药出海爆发，2025年BD授权金额创历史新高，2026年一季度已超600亿美元，行业价值加速兑现，资金大举涌入。$舒泰神(SZ300204)$$九安医疗(SZ002432)$创新药板块大涨，是行情反转还是超跌反弹？核心概念股全梳理创新药板块迎来强势拉升，市场热议这是否意味着板块调整已至尾声。个人整理了创新药核心概念股及赛道逻辑。一、综合型创新药龙头恒瑞医药：国内创新药龙头，研发投入稳居第一，覆盖肿瘤、自免、麻醉、代谢四大核心领域；已获批19款1类创新药，卡瑞利利珠单抗、阿帕替尼、吡咯替尼为核心爆款，2025年创新药收入占比突破60%。百济神州：全球化布局领先，中美欧三地同步推进研发与商业化；核心产品泽布替尼（海外年销超50亿元）、替雷利珠单抗，肿瘤、自免、血液瘤管线全面覆盖。复星医药：“创新药+疫苗+器械+医疗服务”多轮驱动；CAR-T核心产品阿基仑赛国内领先，小分子、生物药、ADC全赛道布局，协同效应显著。科伦药业：输液+创新药双轮驱动；ADC、双抗、小分子领域全面推进，SKB264（TROP2-ADC）等核心品种进入临床关键阶段，商业化潜力大。二、ADC/双抗赛道荣昌生物：国产ADC龙头，维迪西妥单抗（国内首款自研ADC）+泰它西普（自免领域）双轮支撑；与艾伯维达成26亿美元授权出海，创下国产药企里程碑。百利天恒：双抗+ADC技术平台双轮发力，覆盖肿瘤、糖尿病领域；多款双抗/ADC产品进入临床阶段，2025年业绩预计实现高增长。乐普生物：聚焦ADC细分领域，布局Claudin18.2、HER2等热门靶点；多款ADC药物进入临床阶段，研发进度处于行业前列。百奥泰：生物类似药+创新双抗/ADC协同发展；TROP2-ADC、HER2双抗等管线稳步推进，研发与商业化形成互补。三、小分子创新药（靶点明确、业绩兑现强）信立泰：心血管+代谢领域龙头，布局GLP-1、小核酸、肾性贫血等前沿靶点；阿利沙坦酯、S086等核心产品持续放量，增长动能充足。艾力斯：肺癌精准治疗标杆，伏美替尼（三代EGFR-TKI）年销售额近50亿元；同步布局EGFR exon20ins等前沿靶点，管线延续性强。诺诚健华：肿瘤+自免领域双轮驱动，奥布替尼（BTK抑制剂）、ICP-192（FGFR抑制剂）核心产品商业化顺利，研发管线持续丰富。贝达药业：小分子创新药标杆，埃克替尼、恩沙替尼为核心营收支撑；布局KRAS、EGFR等前沿靶点，研发与业绩协同增长。迪哲医药：肺癌精准治疗突破，舒沃替尼（EGFR exon20ins）实现中美双报，全球III期临床试验成功，国际化潜力突出。海创药业：聚焦泌尿系统肿瘤，德恩鲁胺（AR拮抗剂）为前列腺癌核心用药；泌尿系统肿瘤管线布局完善，差异化优势明显。四、自免/代谢/慢病（消费医疗属性凸显）君实生物：PD-1领域先行者，特瑞普利单抗（国产首款PD-1）持续放量；覆盖自免、肿瘤、抗感染等多领域，研发管线迭代快速。信达生物：PD-1（信迪利单抗）商业化领先，年销售额超30亿元；布局双抗、ADC等创新剂型，PD-L1/TROP2双抗ADC进入临床阶段。华东医药：医美+医药协同，布局利拉鲁肽、司美格鲁肽等热门产品；GLP-1口服制剂研发领先，消费属性与创新药增长共振。甘李药业（：胰岛素+GLP-1双赛道，胰岛素周制剂GZR4、博凡格鲁肽（双周GLP-1）出海欧盟获批，国际化与国产化双重驱动。海思科：麻醉、肠外营养、肝病领域为基础，创新药+特色仿制药并行；多款创新药进入临床阶段，研发与现有业务互补。五、生物药/疫苗/特色领域（技术与赛道壁垒并存）舒泰神：神经+消化领域深耕，苏肽生（神经修复核心药）为营收基石；布局小核酸、补体抑制剂等创新赛道，研发方向具备前瞻性。三生国健：自免生物药龙头，益赛普（TNF-抑制剂）市场份额领先；布局双抗、融合蛋白等创新管线，延续自免领域优势。康希诺：mRNA疫苗技术领先，覆盖新冠、带状疱疹等适应症；吸入式疫苗技术具备差异化，研发与商业化潜力突出。智飞生物：HPV疫苗代理+自主结核疫苗双轮驱动，稳定现金流支撑创新研发；研发管线持续迭代，长期竞争力较强。六、CXO/创新药服务（产业链配套核心）药明康德：全球CXO龙头，覆盖药物发现→临床研究→商业化生产全流程；小分子、细胞基因治疗等领域全覆盖，行业壁垒极高。泰格医药：临床CRO龙头，提供I-IV期临床、数据管理等全服务；具备全球多中心临床试验能力，合作客户覆盖国内外药企。康龙化成：小分子CDMO+临床CRO协同，覆盖药物发现、工艺开发、生产全链条；研发与生产配套能力完善，行业竞争力强。昭衍新药：临床前安评龙头，拥有实验动物资源核心壁垒；提供安全性评价、药效学研究等服务，是创新药研发不可或缺的配套环节。七、转型/特色原料药美诺华：从特色原料药向创新药转型，布局非药型GLP-1减重、小核酸领域；实现原料药与制剂一体化发展，转型节奏清晰。华海药业：原料药+制剂双轮驱动，抢滩GLP-1专利到期市场；国际化申报能力强，创新转型与现有业务协同明显。联环药业：扬州国资背景，布局糖尿病创新药LH-1801；拥有6个创新药管线，仿创结合模式清晰，成长潜力突出。今天属于典型的情绪修复性普涨。领涨的医药和半导体板块，背后都有景气度回升或业绩预期的逻辑支撑。不过，地缘局势的后续演变仍是影响市场节奏的关键变量，短期内大盘更可能呈现震荡分化。

2026-04-02

·北京医学感染与传染研究

柳叶刀传染病学 26卷 1-4期

THE LANCET Infectious Diseases. Volume 26Number 1 柳叶刀传染病学 26卷 1期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Urgent need for infection prevention and control in prisons 监狱中感染预防和控制的迫切需求 The Lancet Infectious Diseases The Lancet Infectious Diseases Vol 26(1):p1 COMMENT（述评） 2 Now is the time to integrate serology into routine infectious disease surveillance 现在是时候将血清学纳入常规传染病监测了 Simon Cauchemez The Lancet Infectious Diseases Vol 26(1):p2 3 Reassessing sotrovimab's role in COVID-19: insights and implications 重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示 Daniele Focosi,Fabrizio Maggi The Lancet Infectious Diseases Vol 26(1):p3 4 Shaping opportunities for future clinical trials in tuberculosis 为未来结核病临床试验创造机会 Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich The Lancet Infectious Diseases Vol 26(1):p5 5 Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda 乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化 Arjen M Dondorp The Lancet Infectious Diseases Vol 26(1):p6 6 A safe start for PfSPZ Vaccine, but efficacy in children remains elusive PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸 Nicholas Aderinto,Temitomi Jane Oyedele The Lancet Infectious Diseases Vol 26(1):p8 7 Rifasutenizol-based triple therapy for Helicobacter pylori infection 以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染 Jinnan Chen,Hong Lu The Lancet Infectious Diseases Vol 26(1):p9 8 The smallest faith 最渺小的信念 Steven A Pergam The Lancet Infectious Diseases Vol 26(1):p11 9 Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease 新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标 Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson The Lancet Infectious Diseases Vol 26(1):p13 10 Strengthening global preparedness and response to arboviral disease threats: a call to action 加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁 WHO Global Arbovirus Initiative Technical Advisory Group 世界卫生组织全球虫媒病毒倡议技术咨询小组 The Lancet Infectious Diseases Vol 26(1):p15 11 Introducing our cover artist for 2026: Daria Lada 介绍我们2026年的封面艺术家：达里亚·拉达 Marco De Ambrogi The Lancet Infectious Diseases Vol 26(1):p17 Correspondence（读者来信） 12 Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2 新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况 Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann The Lancet Infectious Diseases Vol 26(1):e1 13 Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响 Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens The Lancet Infectious Diseases Vol 26(1):e3 14 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致 Nader Ebrahimi,Amir Ghaemi The Lancet Infectious Diseases Vol 26(1):e6 15 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复 Frank Aarestrup,Marion Koopmans The Lancet Infectious Diseases Vol 26(1):e7 16 Time to tackle vaccine–HLA associations with artificial intelligence 是时候用人工智能解决疫苗-人类白细胞抗原关联问题了 Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington The Lancet Infectious Diseases Vol 26(1):e8 Corrections（更正） 17 Correction to Lancet Infect Dis 2025; published online Oct 29. 《柳叶刀-传染病》2025年更正；在线发表于10月29日 https://doi.org/10.1016/S1473-3099(25)00466-9 The Lancet Infectious Diseases Vol 26(1):e9 18 Correction to Lancet Infect Dis 2025; published online Oct 27. 《柳叶刀-传染病》2025年更正；在线发表于10月27日 https://doi.org/10.1016/S1473-3099(25)00546-8 The Lancet Infectious Diseases Vol 26(1):e9 19 Correction to Lancet Infect Dis 2025; 25: 1084–96 《柳叶刀-传染病》2025年更正；25卷：1084-1096页 The Lancet Infectious Diseases Vol 26(1):e9 20 Correction to Lancet Infect Dis 2025; published online Nov 10. 《柳叶刀-传染病》2025年更正；在线发表于11月10日 https://doi.org/10.1016/S1473-3099(25)00550-X The Lancet Infectious Diseases Vol 26(1):e9 Newsdesk（新闻台） 21 Highlights of IDWeek 2025 2025年IDWeek亮点 Phoebe Hall The Lancet Infectious Diseases Vol 26(1):e10 22 WHO publishes update on global antibiotic resistance 世界卫生组织发布全球抗生素耐药性最新情况 Timothy Jesudason The Lancet Infectious Diseases Vol 26(1):e11 23 European Commission to fund new medicines for dengue 欧盟委员会资助登革热新药研发 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):e12 24 Second report from the UK Covid-19 Inquiry 英国新冠肺炎调查第二次报告 Talha Burki The Lancet Infectious Diseases Vol 26(1):e13 25 Infectious disease surveillance update 传染病监测最新情况 Cahal McQuillan The Lancet Infectious Diseases Vol 26(1):e14 26 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases Vol 26(1):e15 Obituary（讣告） 27 Jean Louis Abdourahim Ndiaye 让·路易斯·阿卜杜拉希姆·恩迪亚耶 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):p19 Profile（人物介绍） 28 Fortunate Machingura—tackling climate change and disease 福图纳特·马辛古拉——应对气候变化与疾病 Tony Kirby The Lancet Infectious Diseases Vol 26(1):p20 Media Watch（媒体观察） Book（书籍） 29 The social and political drivers behind pandemics 大流行背后的社会和政治驱动因素 Emma Louise Fabiani The Lancet Infectious Diseases Vol 26(1):p21 Articles（论著） 30 Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study 新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究 Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek The Lancet Infectious Diseases Vol 26(1):p22 31 Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial 索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验 RECOVERY Collaborative Group RECOVERY协作组 The Lancet Infectious Diseases Vol 26(1):p34 32 A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial 含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验 John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team The Lancet Infectious Diseases Vol 26(1):p46 33 Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories 2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析 Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar The Lancet Infectious Diseases Vol 26(1):p55 34 Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial 乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验 Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka The Lancet Infectious Diseases Vol 26(1):p67 35 Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial 加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验 Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller The Lancet Infectious Diseases Vol 26(1):p79 36 Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究 Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda The Lancet Infectious Diseases Vol 26(1):p91 37 Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial 以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验 Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group The Lancet Infectious Diseases Vol 26(1):p101 Series（专题研讨会） 38 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Innovation in active and passive immunisation of people who are immunocompromised: a call to action 免疫功能低下人群主动和被动免疫接种的创新：行动呼吁 Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa The Lancet Infectious Diseases Vol 26(1):e16 39 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship 应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理 Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo The Lancet Infectious Diseases Vol 26(1):e30 Review（综述） 40 Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project 揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述 Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro The Lancet Infectious Diseases Vol 26(1):e49 Personal View（个人观点） 41 Azithromycin mass drug administration: balancing survival benefits and risks in children 阿奇霉素大规模药物给药：平衡儿童生存益处与风险 Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro The Lancet Infectious Diseases Vol 26(1):e62 Clinical Picture（临床影像） 42 Unexpected finding in a 17-year-old female undergoing screening colonoscopy 17岁女性接受筛查结肠镜检查时的意外发现 Ziheng Calvin Xu,Ethan Tan,Mayur Garg The Lancet Infectious Diseases Vol 26(1):e75 THE LANCET Infectious Diseases. Volume 26Number 2 柳叶刀传染病学 26卷 2期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Call for letters 征稿启事 The Lancet Infectious Diseases The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111 Comment（述评） 2 Long COVID is here to stay—even in children 长期新冠症状将持续存在——即使在儿童中亦是如此 Danilo Buonsenso The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112 3 Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment 利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用 Ming Hong Choi,Ivan Fan Ngai Hung The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113 4 A new monoclonal in the arMAMentarium against malaria 抗疟“武器库”中的新型单克隆抗体 Freia-Raphaella Lorenz,Matthew B B McCall The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115 5 Household transmission of mpox in Africa: limited in adults but more prevalent in children 非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍 Oriol Mitjà,Michael Marks The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117 6 The lasting lessons of mpox: infection, vaccination, and immune memory 猴痘带来的持久教训：感染、疫苗接种和免疫记忆 Raianna Fantin,Camila H Coelho The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118 7 Xpert-Ultra for diagnosing asymptomatic tuberculosis Xpert-Ultra用于诊断无症状结核病 Xia Yu,Hairong Huang The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120 8 The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action 基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动 David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122 Correspondence（读者来信） 9 Spillover in dengue trials 登革热试验中的溢出效应 Thomas A Smith,Samuel I Watson The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77 10 Spillover in dengue trials – Author's reply 登革热试验中的溢出效应——作者回复 Fernando Abad-Franch The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78 11 Updating the traditional voriconazole trough concentration range 传统的伏立康唑谷浓度范围更新 Rongqiang Liao,Xiaoyuan Zheng The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79 12 Updating the traditional voriconazole trough concentration range – Authors' reply 传统的伏立康唑谷浓度范围更新——作者回复 Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80 13 Clinical course and neurological profile of Kyasanur Forest disease 基萨努尔森林病的临床病程和神经特征 Nitin Gupta,Tirlangi Praveen Kumar The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82 Corrections（更正） 14 Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7 对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7 The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83 15 Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4 对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4 The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83 Newsdesk（新闻台） 16 Promising early data for sorfequiline 索氟维林早期数据令人鼓舞 Ed Holt The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84 17 Highlights from ASTMH 2025 2025年美国热带医学与卫生学会年会亮点 Marco De Ambrogi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85 18 Brazil approves domestic single-shot dengue vaccine 巴西批准国产单剂登革热疫苗 Marcia Triunfol The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86 19 CDC cuts to childhood vaccine recommendations 美国疾控中心削减儿童疫苗接种建议 Priya Venkatesan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87 20 WHO launches unified plan for coronaviruses 世界卫生组织启动冠状病毒统一计划 Talha Burki The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88 21 Infectious disease surveillance update 传染病监测更新 Cahal McQuillan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89 22 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90 Obituary（讣告） 23 Walter Dowdle 沃尔特·道德尔 Sanjeet Bagcchi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124 Profile（人物简介） 24 Katie Anders—improving global dengue control 凯蒂·安德斯——改善全球登革热防控 Tony Kirby The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125 Media Watch（媒体观察） Film（电影） 25 Eliminating Guinea worm 根除麦地那龙线虫 Sanjeet Bagcchi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126 Articles（论著） 26 Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study 奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究 Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127 27 Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial 口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验 William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139 28 Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial 头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验 David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148 29 Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验 single-blind, randomised, controlled, dose-ranging, phase 2 trial Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160 30 Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial 人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验 Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170 31 Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study 布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究 Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182 32 Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study 比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究 Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190 33 Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study 乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究 Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203 Review（综述） 34 Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge 侵袭性A组链球菌感染：从2022-23年激增中吸取的教训 Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91 35 A clinical practice guideline for tuberculous meningitis 结核性脑膜炎临床实践指南 Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96 36 Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults 缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症 Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112 Personal View（个人观点） 37 A transformation in cholera surveillance 霍乱监测的变革 Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124 Clinical Picture（临床图像） 38 Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing 尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展 Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130 THE LANCET Infectious Diseases. Volume 26Number 3 柳叶刀传染病学 26卷 3期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL（社论） 1 Promises and challenges of AI in infectious diseases 人工智能在传染病领域的承诺与挑战 The Lancet Infectious Diseases The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p213 COMMENT（述评） 2 More real-world evidence for RSV vaccines in the global community 全球范围社区呼吸道合胞病毒（RSV）疫苗的更广泛的现实证据 Kristina L Bajema,Wesley H Self The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p214 3 Rapid diagnostic antigen tests for mpox and the need for decentralised testing—not quite there yet 猴痘快速诊断抗原检测及分散检测的必要性——尚待完善 Daniel Mukadi-Bamuleka,Kevin K Ariën The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p215 4 Solving the data bottleneck for artificial intelligence in infectious diseases 解决传染病人工智能领域的数据瓶颈问题 Cesar de la Fuente-Nunez The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p217 5 Artificial intelligence and One Health: potential for spillover prediction? 人工智能与“同一健康”理念：能否预测病原体外溢？ Marion Koopmans,Istvan Csabai,Daniel Remondini,Emma Snary,Frank Aarestrup The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p219 6 Artificial intelligence in the development of vaccines for infectious diseases 人工智能在传染病疫苗研发中的应用 Steve Black,Shabir A Madhi,Rino Rappuoli The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p221 7 Peer review at The Lancet Infectious Diseases in 2025 2025年《柳叶刀-传染病学》期刊专家评审 Ursula Hofer The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p223 8 Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025 感谢2025年《柳叶刀-传染病学》期刊的统计学及评审专家 The Lancet Infectious Diseases Editors The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e132 CORRESPONDENCE（读者来信） 9 Methodological considerations in the attribution of long COVID to first or second infection 首次或二次感染导致长期新冠症状的方法学考量 Sara Carazo,Danuta M Skowronski,Manale Ouakki,Gaston De Serres The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e139 10 Methodological considerations in the attribution of long COVID to first or second infection – Authors' reply 首次或二次感染导致长期新冠症状的方法学考量——作者回复 Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Christopher B Forrest,Yong Chen The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e141 11 Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2 LP.8.1单价疫苗针对包括XEC、LP.8.1、NB.1.8.1、XFG和BA.3.2在内的多种SARS-CoV-2变异株的体液免疫应答 Yu Kaku,Mizuka Fujiwara,Keiya Uriu,Maximilian Stanley Yo,Shusuke Kawakubo,Jumpei Ito,Naoya Itoh,Yoshifumi Uwamino,Fumitake Saito,Hironori Satoh,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Kei Sato The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e142 12 Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance 金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者 Brenda A Warecki,María F Mojica,Alejandro J Vila,Robert A Bonomo The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e144 13 Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply 金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者——作者回复 David L Paterson,Abdullah T Aslan,Patrick N A Harris The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e145 CORRECTIONS（更正） 14 Correction to Lancet Infect Dis 2025; published online Dec 9. https://doi.org/10.1016/S1473-3099(25)00659-0 《柳叶刀-传染病学》2025年发表文章勘误；在线发表于12月9日。https://doi.org/10.1016/S1473-3099(25)00659-0 The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146 15 Correction to Lancet Infectious Diseases 2026; published online Jan 20. https://doi.org/10.1016/S1473-3099(25)00773-X 《柳叶刀-传染病学》2026年发表文章勘误；在线发表于1月20日。https://doi.org/10.1016/S1473-3099(25)00773-X The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146 NEWSDESK（新闻台） 16 Rabies an increasing threat in Ukraine 乌克兰狂犬病威胁日益加剧 Ed Holt The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e147 17 People needing trachoma interventions at record low 需要沙眼干预措施的人数创历史新低 Timothy Jesudason The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e148 18 Uneven STI response in EU/EEA countries 欧盟/欧洲经济区国家性传播感染应对措施不均衡 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e149 19 Controversial HBV vaccine trial in Guinea-Bissau halted 几内亚比绍有争议的乙型肝炎病毒疫苗试验被叫停 Talha Burki The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e150 20 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e151 OBITUARY（讣告） 21 Ivan Hirsch 伊万·赫希 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p224 PROFILE（人物介绍） 22 Reem Abu Shomar— championing water safety in Gaza 里姆·阿布·舒马尔——加沙地带水安全倡导者 Tony Kirby The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p225 MEDIA WATCH（媒体观察） Book（书籍） 23 A prescription for public health literacy 提升公众健康素养的良方 Vijay Shankar Balakrishnan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p226 Book（书籍） 24 Imagining the inevitable 想象不可避免之事 Cahal McQuillan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p227 Film（电影） 25 Women's autonomy, safe sex and HIV prevention 女性自主权、安全性行为与艾滋病预防 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p228 ARTICLES（论著） 26 Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study 英国75-79岁成年人中双价呼吸道合胞病毒（RSV）预融合F蛋白疫苗对RSV相关住院的有效性：一项多中心、检测阴性、病例对照研究 Rebecca Symes,Heather J Whitaker,Shazaad Ahmad,David Arnold,Suryabrata Banerjee,Cariad M Evans,Robin Gore,Jennifer Hart,Katy Heaney,Onn Min Kon,Anne Melhuish,Munira Ortale Zogaib,Emanuela Pelosi,Najib M Rahman,Gerrit Woltmann,Tricia McKeever,Maria Zambon,Conall H Watson,Wei Shen Lim,Jamie Lopez Bernalon behalf of the HARISS network collaborators The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p229 27 Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial 印度治疗初治慢性肺曲霉病患者口服伊曲康唑与口服伏立康唑的对比研究（VICTOR-CPA试验）：一项单中心、开放标签、随机、对照、优效性试验 Inderpaul Singh Sehgal,Ritesh Agarwal,Sahajal Dhooria,Kuruswamy Thurai Prasad,Valliappan Muthu,Ashutosh Nath Aggarwal,Shivaprakash M Rudramurthy,Mandeep Garg,Arunaloke Chakrabarti The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p239 28 Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial 血流感染抗生素治疗疗程依从性考量（BALANCE）：一项随机临床试验的事后分析 Sean W X Ong,Ruxandra Pinto,Robert K Mahar,Asgar Rishu,Joshua S Davis,Robert A Fowler,Steven Y C Tong,Nick Danemanfor the BALANCE trial consortium The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p250 29 Field evaluation of a rapid antigen test for mpox in the Democratic Republic of the Congo and Uganda: a multicentre, prospective, diagnostic accuracy study 刚果民主共和国和乌干达猴痘快速抗原检测的现场评估：一项多中心、前瞻性、诊断准确性研究 Barnabas Bakamutumaho,David Lupande Mwenebitu,Winters Muttamba,Ingrid Ampeire,Henry Kyobe Bosa,Esto Bahizire,Bertin Casinga Bisimwa,Andrew Obuku,Misaki Wayengera,Alison Sandeman,Matthew T G Holden,Patrick D M C Katoto,Bruce Kirenga,Deborah A Williamson,Wilber Sabiiti The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p260 30 Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis 伤寒热的并发症与死亡率：一项更新的全球系统综述与荟萃分析 Shruti Murthy,Nienke N Hagedoorn,Suzanne Faigan,Meera D Rathan,Christian S Marchello,John A Crump The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p270 31 Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 1990-2023年全球、区域和国家层面查加斯病负担：2023年全球疾病负担研究的系统分析 GBD 2023 Chagas Disease and RAISE Study Collaborators The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p284 32 Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial 乌干达健康成年人中ChAdOx1裂谷热疫苗的安全性、耐受性和免疫原性：一项单中心、单盲、随机、安慰剂对照、剂量递增的1期试验 Zacchaeus Anywaine,Jennifer Serwanga,Abu-Baker Mustapher Ggayi,Andrew Max Abaasa,Daniel Wright,Ben Gombe,Peter Ejou,Tamara Namata,Antony Kigozi,Naboth Tukamwesiga,Vincent Basajja,Violet Ankunda,Dora Jocelyn Mulondo,Florence Nambaziira,Ayoub Kakande,Wilson Kakeeto,Phiona Nabaggala,Daniel Jenkin,Alison Lawrie,Pedro Folegatti,Nguyen Tran,Christian Hansen,Alison M Elliott,Adrian V S Hill,George M Warimwe,Pontiano Kaleebu The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p302 33 Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial 美国儿童、青少年和成人基础免疫后18个月VLA15莱姆病疫苗候选物的加强免疫接种的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的2期试验 Laura Wagner,Michaela Obersriebnig,Romana Hochreiter,Vera Kadlecek,Julian Larcher-Senn,Lisa Hegele,Jason D Maguire,Timothy Murphy,Ulla Derhaschnig,Nicole Bézay,Juan Carlos Jaramillo,Susanne Eder-Lingelbach,Marc Messier The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p314 SERIES（研讨会） Artificial Intelligence and Infectious Diseases 人工智能与传染病 34 Artificial intelligence and infectious diseases: an evidence-driven conceptual framework for research, public health, and clinical practice 人工智能与传染病：基于证据的研究、公共卫生和临床实践概念框架 Anna Odone,Chiara Barbati,Silvia Amadasi,Tanja Schultz,David B Resnik The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e152 35 Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives 人工智能与传染病诊断：现状与未来展望 Luca Miglietta,Timothy M Rawson,Ronald Galiwango,Alex Tasker,Damien K Ming,Darlington Akogo,Cecilia Ferreyra,Eric O Aboagye,N Claire Gordon,Carolina Garcia-Vidal,Jesus Rodriguez-Manzano,Alison H Holmes The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e168 36 Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery 人工智能与传染病：应对抗菌药物耐药性，从个性化治疗到抗生素发现 Alex Howard,Nada Reza,Peter L Green,Mo Yin,Erin Duffy,Henry C Mwandumba,Alessandro Gerada,William Hope The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e181 REVIEW（综述） 37 Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia 血液系统恶性肿瘤患者或接受造血细胞移植患者社区获得性呼吸道病毒感染：第10届欧洲白血病感染会议更新建议 Marie von Lilienfeld-Toal,Fareed Khawaja,Francesca Compagno,Christine Robin,José-Luis Piñana,Simone Cesaro,Hermann Einsele,Per Ljungman,David Navarro,Michael Boeckh,Roy F Chemaly,Hans H Hirsch The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e193 CLINICAL PICTURE（临床图像） 38 Mycoplasma hominis toe osteomyelitis: a rare and unusual bone infection 人型支原体足趾骨髓炎：一种罕见且不寻常的骨感染 Cheryl Keel,Pauleen McSherry,Rebecca Thombre,Sendurann Nadarajah,Rediat Tewolde,Owen B Spiller,Baharak Afshar The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e207 THE LANCET Infectious Diseases. Volume 26Number 4 柳叶刀传染病学 26卷 4期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 GoGoVax dispels hopes for gonorrhoea vaccination GoGoVax让淋病疫苗的希望破灭 The Lancet Infectious Diseases The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p329 COMMENT（述评） 2 Do the benefits of universal screening outweigh the harms? 全民筛查的益处是否大于害处？ Alanna N Gillespie,Emma Webb,Valerie Sung The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p330 3 Chikungunya in Brazil: vaccination strategies informed by mathematical modelling 巴西基孔肯雅热：基于数学建模的疫苗接种策略 José Lourenço,Marta Giovanetti The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p331 4 Chikungunya adolescent vaccination and the distinct risk–benefit landscapes 青少年接种基孔肯雅热疫苗及独特的风险-获益情况 Ernesto T A Marques,Simon Barratt-Boyes The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p333 5 Circulation of clade Ib mpox outside of Africa—are we prepared? 非洲以外地区Ib分支猴痘的传播——我们准备好了吗？ Seth D Judson,Claude Kwe Yinda,Franziska K Kaiser,Daniel S Chertow,Emmie de Wit,James O Lloyd-Smith,Vincent J Munster The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p334 6 I worked at WHO: the USA leaving will not make America healthier 我曾在世卫组织工作：美国退出不会让美国更健康 Krutika Kuppalli The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p336 CORRESPONDENCE（读者来信） 7 Maternal views on RSV vaccination in the UK's second season 英国第二季呼吸道合胞病毒疫苗接种的产妇观点 Shaun O'Hagan,Steve Cunningham,Simon B Drysdale,Helen E Groves,Samantha Hunt,Dalia Iskander,Xinxue Liu,Mark D Lyttle,Chengetai D Mpamhanga,Thomas Waterfield,Thomas C Williams,Robin Marlow,Damian Rolandon behalf of the PERUKI & BronchStart/Stop Collaboration The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e209 8 Overcoming immune imprinting with the COVID-19 LP.8.1 mRNA boosters 利用COVID-19 LP.8.1 mRNA加强针克服免疫印记 Ninaad Lasrado,Annika Rössler,Katherine Molloy,Isabella McConnell,Ritobhas Bhowmik,Francisco Armando Granados-Contreras,Jessica Wu,Alejandra Waller-Pulido,Samuel J Nangle,Erica Borducchi,Ai-ris Y Collier,Dan H Barouch The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e212 CORRECTIONS（更正） 9 Correction to Lancet Infect Dis 2025; published online Nov 27. https://doi.org/10.1016/S1473-3099(25)00605-X 《柳叶刀-传染病学》2025年刊载内容更正；在线发布于11月27日 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 10 Correction to Lancet Infect Dis 2026; 26: 343–61 《柳叶刀-传染病学》2026年刊载内容更正；26卷：343-61页 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 11 Correction to Lancet Infect Dis 2026; published online Jan 23. https://doi.org/10.1016/S1473-3099(25)00730-3 《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月23日 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 12 Correction to Lancet Infect Dis 2026; published online Jan 28. https://doi.org/10.1016/S1473-3099(25)00747-9 《柳叶刀-传染病学》2026年刊载内容更正；在线发布于1月28日 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e214 NEWSDESK（新闻台） 13 UK loses measles elimination status as cases rise 随着病例增加，英国失去麻疹消除地位 Priya Venkatesan The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e215 14 Brazil launches implementation study of lenacapavir 巴西启动来那卡帕韦实施研究 Tony Kirby The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e216 15 Clade Ib mpox in southwest Indian Ocean islands 西南印度洋岛屿出现Ib分支猴痘 Esther Nakkazi The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e217 16 EMA approves combined COVID-19 and flu mRNA vaccine 欧洲药品管理局批准COVID-19和流感联合mRNA疫苗 Talha Burki The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e218 17 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e219 OBITUARY（讣告） 18 Nicholas John White 尼古拉斯·约翰·怀特 Sanjeet Bagcchi The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p339 PROFILE（人物简介） 19 Katharina Kranzer—led by curiosity, committed to capacity 卡塔琳娜·克兰泽——受好奇心驱使，致力于提升能力 Tony Kirby The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p340 MEDIA WATCH（媒体观察） Film（电影） 20 Leishmaniasis: a story of two continents 利什曼病：两个大陆的故事 Vijay Shankar Balakrishnan The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p341 Book（书籍） 21 Finding your voice in a world of uncertainty 在不确定的世界中找到自己的声音 Carrie Fielden The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p342 ARTICLES（论著） 22 Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 1990-2023年下呼吸道感染的全球负担及病因：2023年全球疾病负担研究的系统分析 GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators GBD 2023下呼吸道感染和抗菌素耐药性协作组 The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p343 23 Effectiveness of the maternal RSVpreF vaccine against severe disease in infants in Scotland, UK: a national, population-based case–control study and cohort analysis 英国苏格兰地区母体RSVpreF疫苗对婴儿严重疾病的保护效果：一项全国性、基于人群的病例对照研究和队列分析 Isobel McLachlan,Chris Robertson,Kirsty E Morrison,Ross McQueenie,Safraj Shahul Hameed,Cheryl Gibbons,Rachael Wood,Rachel Merrick,Louisa Pollock,Antonia Ho,Ting Shi,Thomas C Williams,Sir Aziz Sheikh,Jim McMenamin,Sam Ghebrehewet,Kimberly Marsh The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p362 24 Post-COVID-19 resurgence of Mycoplasma pneumoniae infections in French children (ORIGAMI): a retrospective and prospective multicentre cohort study 法国儿童COVID-19后支原体肺炎感染的复现（ORIGAMI）：一项回顾性和前瞻性多中心队列研究 Anaïs Chosidow,Zoha Maakaroun-Vermesse,Vichita Ok,Cécile Delecroix,Pascal Le Roux,Marie-Aliette Dommergues,Justine de Larminat,Eric Jeziorski,Pauline Ronjat,Léa Jaume,Anne Welfringer-Morin,Cécile Bébéar,Maud Gits-Muselli,Delphine Viriot,Charles-Joris Roux,Stéphane Bechet,Anne-Sophie Romain,Mathie Lorrot,Robert Cohen,Corinne Levy,Jérémie F Cohenon behalf of the ORIGAMI Study Group The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p374 25 Lessons derived from a 3-year congenital cytomegalovirus screening programme in Israel: a prospective population-based cohort study 以色列先天性巨细胞病毒筛查项目的3年经验教训：一项前瞻性基于人群的队列研究 Smadar Eventov Friedman,Noa Ofek Shlomai,Esther Oiknine-Djian,Tal Sido,Oren Gordon,Sraya Greenberger,Hadar Horowitz,Lior Merav,Stav David Mehaber,Orit Caplan,Miriam Geal-Dor,Natalia Simanovsky,Diana Averbuch,Colin Kunzweiler,Yosefa Hefter,John Diaz-Decaro,Ora Paltiel,Moran Yassour,Dana G Wolf The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p384 26 Comparison of the performance and costs of testing algorithms using rapid diagnostic tests for detection and treatment of syphilis among pregnant individuals and men who have sex with men: a modelling study 使用快速诊断检测方法对孕妇和男男性行为者进行梅毒检测和治疗的不同检测算法的性能和成本比较：一项建模研究 Ying Zhang,Eric P F Chow,Lei Zhang,Christopher K Fairley,Jason J Ong The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p394 27 The epidemiology of chikungunya virus in Brazil and the potential impact of vaccines: a mathematical modelling study 巴西基孔肯雅热病毒的流行病学及疫苗的潜在影响：一项数学建模研究 Oscar Cortes-Azuero,Megan O'Driscoll,Gabriel Ribeiro dos Santos,Ronaldo de Jesus,Shirlene T S de Lima,Danny Scarponi,Christinah Mukandavire,Arminder Deol,Moritz U G Kraemer,William M de Souza,Henrik Salje The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p406 28 Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil 青少年接种减毒活基孔肯雅热病毒疫苗的安全性和免疫原性：巴西流行地区一项为期12个月、双盲、随机、安慰剂对照的3期试验最终结果 Vera Buerger,Andrea Pfeiffer,Petra Schoengrundner,Jutta Seebacher,Romana Hochreiter,Karin Kosulin,Oliver Zoihsl,Petronela Weisova,Robert Mader,Ana Paula Loch,Eolo Morandi Jr,Mauricio Lacerda Nogueira,Carlos Alexandre Antunes de Brito,Julio Croda,Mauro Martins Teixeira,Ivo Castelo-Branco Coelho,Ricardo Gurgel,Allex Jardim da Fonseca,Marcus Vinícius Guimarães de Lacerda,Edson Duarte Moreira Jr,Ana Paula Rocha Veiga,Susanne Eder-Lingelbach,Juan Carlos Jaramillo The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p417 29 National burden of and optimal vaccine policy for Japanese encephalitis virus in Bangladesh: a seroprevalence and modelling study 孟加拉国日本脑炎病毒的全国负担及最佳疫苗接种政策：一项血清流行率和建模研究 Mariana Perez Duque,Kishor K Paul,Rebeca Sultana,Gabriel Ribeiro dos Santos,Megan O'Driscoll,Abu M Naser,Mahmudur Rahman,Mohammad Shafiul Alam,Hasan M Al-Amin,Mohammed Z Rahman,Mohammad E Hossain,Repon C Paul,Elias Krainski,Stephen P Luby,Simon Cauchemez,Jessica Vanhomwegen,Emily S Gurley,Henrik Salje The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：p429 REVIEW（综述） 30 Autoantibodies in long COVID: a systematic review 长新冠中的自身抗体：一项系统综述 Fabian Wilhelm,Janne Cadamuro,Sylvia Mink The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e220 31 Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE) 登革热临床试验核心结局测量指标集：一项国际德尔菲共识研究（DEN-CORE） Sophie Yacoub,Anastasia Demidova,Xin Hui S Chan,Ali Ajam,Dina Baimukhambetova,Andreij Horn,Evgeniia Kakotkina,Mark Kosenko,Aigun Mursalova,Jennifer Ilo Van Nuil,Chi Le Phuong,Lin Xiao,Sudeep Adhikari,Juan David Alzate Alvarez,Kathryn B Anderson,Panisadee Avirutnan,Stephanie Buchholz,Richa Chandra,Aileen Y Chang,Ho Quang Chanh,Mónika Patricia Consuegra Rodríguez,Vanessa Daniel,Janet V Diaz,Claudia Figueiredo-Mello,Rosa Margarita Gelvez-Ramírez,Tran Bang Huyen,Evelyne Kestelyn,Phung Khanh Lam,Stije J Leopold,Ruobing Li,Tran Luu,David Chien Boon Lye,Angela McBride,Isabelle Meyer-Andrieux,Nathaniel J Moorman,Nguyet Minh Nguyen,Sharifah Faridah Syed Omar,Hang Cheng Ong,Eng Eong Ooi,Ekaterina Pazukhina,Sarah L Pett,Diego Bastos Porto,Giri S Rajahram,Marc Rogers,Elsa Rojas,James Rosen,Jamie Rylance,William H K Schilling,Andre M Siqueira,Peter Sjö,Alfonso Sucerquia-Hernandez,Dong Thi Hoai Tam,Mauro Martins Teixeira,Andreas Tietz,Huynh Trung Trieu,Annalise Unsworth,Luis Villar,Adam Tully Waickman,James A Watson,Bridget A Wills,Po Ying Chia,Patricia Brasil,Thomas Jaenisch,Lucy Lum,Gathsaurie Neelika Malavige,Steven McGloughlin,Bharath Kumar Tirupakuzhi Vijayaraghavan,Laura Merson,Daniel Munblitthe DEN-CORE Study Group The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e231 PERSONAL VIEW（个人观点） 32 Breaking the under-reporting cycle for zoonotic diseases in low-income and middle-income countries through national-level integration of community-based surveillance and response: insights from Cameroon, Chad, Côte d’Ivoire, and Mali 通过国家层面整合社区监测和响应，打破低收入和中等收入国家人畜共患病报告不足的循环：来自喀麦隆、乍得、科特迪瓦和马里的见解 Katherine E L Worsley-Tonks,Mahamat Fayiz Abakar,Zanan Coulibaly,Marie Paulette Deya-Yang,Linda Esso,Jean Marc Kameni Feussom,Vessaly Kallo,Zakaria Keita,Monique Lechenne,Magloire Tchamba Kombou,Inès Emah Manda,Christiane Mangou,Stephanie Mauti,Aime Gilert Mbonda Noula,Rodrigue Poueme Namegni,Perrine Parize,Mathurin Cyrille Tejiokem,Isaac Tiembre,Abdallah Traoré,Jakob Zinsstag,Hervé Bourhy The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e245 GRAND ROUND（大查房） 33 Paediatric case of invasive group A streptococcal necrotising myositis: diagnostic challenges and lessons learned 儿童侵袭性A组链球菌坏死性肌炎病例：诊断挑战和经验教训 Suraya Yusuf,Michael James Carter,Jenny Woodruff,Peter Kalu,Justin Conrad Rosen Wormald,Claire Sethu The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e259 CLINICAL PICTURE（临床图像） 34 Bullous haemorrhagic cellulitis caused by Escherichia coli in a patient with cirrhosis 肝硬化患者由大肠杆菌引起的大疱性出血性蜂窝织炎 Irene Rivera-Ruiz,Paloma Elma Alañón-Martínez,Elisa Vidal-Verdú The Lancet Infectious Diseases. Apr 2026，Vol 26(4)：e268

100 项与马来酸吡咯替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01XE	DB14993

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
晚期 HER2 阳性乳腺癌	中国	江苏恒瑞医药股份有限公司	2023-04-17
HER2阳性乳腺癌	中国	江苏恒瑞医药股份有限公司	2018-08-12

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HER2低表达乳腺癌	临床3期	中国	江苏恒瑞医药股份有限公司	2024-01-17
HR阳性乳腺癌	临床3期	中国	江苏恒瑞医药股份有限公司	2024-01-17
HR阳性/HER2低表达乳腺癌	临床3期	中国	江苏恒瑞医药股份有限公司	2024-01-17
浸润性乳腺癌	临床3期	中国	江苏恒瑞医药股份有限公司	2024-01-17
晚期非小细胞肺癌	临床3期	美国	江苏恒瑞医药股份有限公司	2020-09-11
晚期非小细胞肺癌	临床3期	中国	江苏恒瑞医药股份有限公司	2020-09-11
晚期非小细胞肺癌	临床3期	澳大利亚	江苏恒瑞医药股份有限公司	2020-09-11
晚期非小细胞肺癌	临床3期	比利时	江苏恒瑞医药股份有限公司	2020-09-11
晚期非小细胞肺癌	临床3期	法国	江苏恒瑞医药股份有限公司	2020-09-11
晚期非小细胞肺癌	临床3期	德国	江苏恒瑞医药股份有限公司	2020-09-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03863223 (PHILA, Pubmed) 人工标引	临床3期	HER2阳性转移性乳腺癌 HER2 Positive	590	Pyrotinib + Trastuzumab + Docetaxel	鹹淵築獵鹽鹽蓋繭鏇廠(廠鏇積窪餘衊廠顧製鬱) = 顧襯蓋衊製築選築醖淵衊積艱選餘淵艱鬱壓簾 (廠選積獵齋製構顧糧衊, 19.3 ~ 27.8) 更多	优效	2026-03-16
				Placebo + Trastuzumab + Docetaxel	鹹淵築獵鹽鹽蓋繭鏇廠(廠鏇積窪餘衊廠顧製鬱) = 襯憲艱築獵醖鑰蓋鬱遞衊積艱選餘淵艱鬱壓簾 (廠選積獵齋製構顧糧衊, 9.5 ~ 12.4) 更多
NCT03863223 (PHILA, SABCS2025) 人工标引	临床3期	HER2阳性转移性乳腺癌一线 HER2 Positive	590	Pyrotinib + Trastuzumab + Docetaxel	鑰醖鹹鬱艱觸蓋鹹鏇壓(製醖遞鑰艱襯壓簾餘淵) = 膚鏇遞鹽構獵齋顧鬱築醖觸鑰艱獵廠積鹹憲願 (鏇顧鏇遞願窪簾壓齋鏇, 19.2 ~ NE) 更多	积极	2025-12-12
				Placebo + Trastuzumab + Docetaxel	鑰醖鹹鬱艱觸蓋鹹鏇壓(製醖遞鑰艱襯壓簾餘淵) = 憲憲鏇鹽廠衊憲鬱餘遞醖觸鑰艱獵廠積鹹憲願 (鏇顧鏇遞願窪簾壓齋鏇, 6.4 ~ 13.2) 更多
NCT07014410 (SYSUCC-002, SABCS2025)	临床2期	HER2阳性转移性乳腺癌一线 HER2-Positive \| Estrogen Receptor-Positive	16	PyrotinibDalpiciclibLetrozoleib + PyrotinibDalpiciclibLetrozole + PyrotinibDalpiciclibLetrozole (Estrogen Receptor-Positive and HER2-Positive Metastatic Breast Cancer)	繭選積壓獵壓膚製鹽範(廠鬱淵選鏇醖積窪蓋簾) = 餘願遞製構構築艱襯鑰網憲膚壓襯鏇選觸製鹹 (壓築艱構鑰鹽衊壓鹽壓, 41 ~ 88)	积极	2025-12-12
SABCS2025	N/A	HER2阳性乳腺癌巩固 HER2-Positive	104	Pyrotinib 400 mg/day	選積願餘壓蓋選艱壓觸(範繭壓獵簾繭獵鏇鏇襯) = 選鏇艱艱窪憲醖廠獵淵顧願積夢顧築襯膚廠積 (淵顧壓壓願網夢餘餘選 ) 更多	积极	2025-12-11
SABCS2025	N/A	HER2阳性乳腺癌新辅助 HR+ \| HER2-positive	104	Pyrotinib-containing regimen	鏇獵憲壓憲選獵鏇廠蓋(獵選製選淵獵鑰觸選壓) = 襯夢衊網膚積積膚醖憲糧築遞選憲選積網鹽鏇 (廠繭襯顧獵遞衊蓋製蓋 ) 更多	积极	2025-12-11
NCT05292742 (KATHERINE, SABCS2025)	临床2期	HER2阳性乳腺癌辅助 HER2-positive	102	CapecitabinePyrotinibTrastuzumab + CapecitabinePyrotinibTrastuzumab + CapecitabinePyrotinibTrastuzumabe (HER2-positive early breast cancer + Non-pCR)	餘獵繭淵夢齋鬱廠選簾(積窪獵選餘範廠構網鹽) = 糧夢齋選構膚齋製鹽鏇鏇衊窪淵構網餘壓淵願 (窪鏇餘醖鏇壓壓願範築, 83.3 ~ 95.6) 更多	积极	2025-12-11
ESMO_ASIA2025	N/A	HER2阳性转移性乳腺癌 HER2-positive	337	Pyrotinib	壓齋襯糧憲繭淵鏇淵憲(鏇窪繭積蓋選夢憲構鹽) = 願鬱鏇憲構衊獵膚網網鬱鑰繭襯願築夢鹽網鬱 (壓壓願蓋憲窪構憲壓鹽, 12.9 ~ 17.6) 更多	积极	2025-12-05
				Pyrotinib (First-line treatment)	壓齋襯糧憲繭淵鏇淵憲(鏇窪繭積蓋選夢憲構鹽) = 獵範顧鏇繭齋選顧膚築鬱鑰繭襯願築夢鹽網鬱 (壓壓願蓋憲窪構憲壓鹽, 10.1 ~ 32.6) 更多
ESMO_ASIA2025	N/A	HER2阳性转移性乳腺癌一线 HER2-positive	411	Docetaxel+Trastuzumab+Pyrotinib	淵繭夢淵襯鹹獵醖範壓(膚鑰醖範夢築艱鏇壓餘) = 顧鑰鹽簾蓋壓襯醖顧襯淵鏇顧糧製齋餘醖鹽繭 (襯積淵顧觸繭鬱築鹽觸, 21.2 ~ 30.4) 更多	积极	2025-12-05
				Taxane+Trastuzumab+Pertuzumab	淵繭夢淵襯鹹獵醖範壓(膚鑰醖範夢築艱鏇壓餘) = 淵鹽鑰鹽網艱構範積鏇淵鏇顧糧製齋餘醖鹽繭 (襯積淵顧觸繭鬱築鹽觸, 13.2 ~ 23.3) 更多
ESMO2025	N/A	HER2阳性转移性乳腺癌 HER2+	301	Inetetamab + Pyrotinib + Chemotherapy	廠鹹觸膚願顧獵觸糧願(膚選遞壓觸遞憲築艱遞) = 築鹹遞膚齋製製窪壓獵夢艱齋鏇積艱觸蓋艱膚 (製齋鏇齋築淵遞餘獵簾, 9.8 ~ 14.2) 更多	积极	2025-10-17
				Inetetamab + Pyrotinib + Chemotherapy (1st line)	廠鹹觸膚願顧獵觸糧願(膚選遞壓觸遞憲築艱遞) = 壓齋願衊鬱鹽鏇範夢鑰夢艱齋鏇積艱觸蓋艱膚 (製齋鏇齋築淵遞餘獵簾 )
NCT04486911 (MUKDEN 01, ESMO2025)	临床2期	ER阳性/PR阳性/HER2阳性乳腺癌一线 \| 新辅助 ER Positive \| PR Positive \| HER2 Positive	81	Pyrotinib+Letrozole+Dalpiciclib	衊餘膚壓遞築築鬱範艱(鏇鬱夢顧鑰製鏇積遞簾) = 衊壓餘糧繭鑰膚廠膚憲願淵繭網餘選獵夢網網 (願艱淵鏇選憲顧窪糧顧, 88.6 ~ 99.1) 更多	积极	2025-10-17